ZVRA logo

ZVRA
Zevra Therapeutics Inc

24,024
Mkt Cap
$499.36M
Volume
726,624.00
52W High
$13.16
52W Low
$6.19
PE Ratio
14.06
ZVRA Fundamentals
Price
$8.87
Prev Close
$8.64
Open
$8.61
50D MA
$9.28
Beta
0.93
Avg. Volume
1.68M
EPS (Annual)
-$2.28
P/B
3.74
Rev/Employee
$400,203.39
Loading...
Loading...
News
all
press releases
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat reports. One...
MarketBeat·16d ago
News Placeholder
More News
News Placeholder
Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC
Stonepine Capital Management LLC boosted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 19.3% in the second quarter, according to the company in its most recent Form...
MarketBeat·23d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Trading Up 3.8% - Here's Why
Zevra Therapeutics (NASDAQ:ZVRA) Trading Up 3.8% - Should You Buy...
MarketBeat·1mo ago
News Placeholder
Campbell & CO Investment Adviser LLC Buys Shares of 83,245 Zevra Therapeutics, Inc. $ZVRA
Campbell & CO Investment Adviser LLC purchased a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the second quarter, according to its most recent Form 13F filing with the...
MarketBeat·1mo ago
News Placeholder
Los Angeles Capital Management LLC Buys Shares of 121,225 Zevra Therapeutics, Inc. $ZVRA
Los Angeles Capital Management LLC purchased a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F...
MarketBeat·1mo ago
News Placeholder
Research Analysts Set Expectations for ZVRA FY2025 Earnings
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at William Blair lifted their FY2025 earnings estimates for Zevra Therapeutics in a research report issued to clients and...
MarketBeat·2mo ago
News Placeholder
FY2025 EPS Estimate for Zevra Therapeutics Raised by Analyst
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to...
MarketBeat·2mo ago
News Placeholder
William Blair Analysts Boost Earnings Estimates for ZVRA
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - William Blair lifted their Q3 2026 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Wednesday, November...
MarketBeat·2mo ago
News Placeholder
FY2026 EPS Estimates for ZVRA Decreased by Cantor Fitzgerald
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2026 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on...
MarketBeat·2mo ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to "Buy" at Wall Street Zen
Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest ZVRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.